Completed
A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects
NCT02135692
- Conditions
- Asthma, Bronchial Diseases, Eosinophilia, +12 more
- Locations
-
- GSK Investigational Site Newport Beach, California, United States
- GSK Investigational Site Riverside, California, United States
- GSK Investigational Site Rolling Hills Estates, California, United States
- GSK Investigational Site Denver, Colorado, United States